There’s good news for Furmonertinib in October.

Since October 1, Furmonertinib has quickly covered 10 cities,and has entered the catalog of drugs of their inclusive medical insurance.

In March last year, the State Council issued "the Opinion on Deepening the Reform of the Medical Security System". Since then, health insurance products such as "Huiminbao" with the inclusive characteristics, have been spreading rapidly in China's cities and regions, to safeguard the masses to obtain high quality, efficient, and affordable medical services, and enhance people's sense of gain, happiness and security.

As an innovative pharmaceutical company focusing on oncology, Allist, adhering to its philosophy of "Advancing Long Life with Innovation of Science and Technology", is actively supporting and participating in this innovative, inclusive medical insurance model, and accelerating the adding of Furmonertinibto local inclusive medical insurance catalogs.

As of October 31, Furmonertinib has been included in 27 inclusive medical insurance catalogs, trying to make Furmonertinib accessible by building all-round and multi-level medical security systems, to benefit more Chinese patients with NSCLC ASAP.

About Allist

Founded in March 2004, Shanghai Allist Pharmaceuticals Co., Ltd. is an innovative drug developer, producer and seller dedicated to the field of lung cancer treatment oriented toward the demands in the global pharmaceutical market. With the philosophy of innovation for life, Allist has set the paramount target of developing first-in-class and best-in-class medicines. After 16 years of unremitting efforts, Allist now boasts strong comprehensive competitiveness in developing and producing on a continuous basis effective and optimal anti-cancer new drugs with independent intellectual property rights.

On December 2, 2020, Shanghai Allist Pharmaceuticals Co., Ltd. went public on the STAR market via the Shanghai Stock Exchange (Stock code: 688578).